One of the bright spots in an otherwise fairly “blah” quarter for GlaxoSmithKline (NYSE:GSK) was the report that Triumeq and Tivicay, two drugs for HIV, were rapidly ramping up sales -- to the tune of about $311 million and $240 million in sales last quarter, respectively. Triumeq and Tivicay are both owned and marketed by ViiV Healthcare, which is a joint venture among GlaxoSmithKline, Pfizer, and Japanese pharma Shionogi. Gilead Sciences (NASDAQ:GILD), the goliath in the HIV space, even mentioned Triumeq on their most recent earnings call, with President John Milligan admitting that “Triumeq has been doing well on its launch, and it has been taking some market share from Gilead” (this and other quotes courtesy of S&P Capital IQ). With analysts estimating up to $5 billion in peak sales for Triumeq and Tivicay, these drugs present an immediate danger to Gilead’s $10 billion HIV franchise.
Help employers find you! Check out all the jobs and post your resume.
